The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there is currently no preventive vaccine, a ...

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says. Though most people recover from the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Unless they’re covering me in a cloud of norovirus particles. When the violent expelling of liquid starts somewhere other ...